Fred D. Lublin, MD, FAAN, FANA: There are several goals in treating multiple sclerosis [MS]. We treat the exacerbations as we have just discussed. We have disease-modifying therapies, which lessen the ...
Roche said its fenebrutinib drug candidate met primary goals in two late-stage trials for multiple sclerosis, reducing attacks or delaying disability progression in two different forms of the disease.
Value-based agreements come with risks and benefits, but a health system’s existing facilities and initiatives can help support the goals associated with them, JT Lew, PharmD, MBA, a managed care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback